Platelet Activating Factor (PAF): A Mediator of Inflammation.
PAF
PAF-AH
anaphylaxis
biomarker
inflammation
mediator
phospholipid
Journal
BioFactors (Oxford, England)
ISSN: 1872-8081
Titre abrégé: Biofactors
Pays: Netherlands
ID NLM: 8807441
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
01
06
2022
accepted:
21
07
2022
pubmed:
28
8
2022
medline:
24
12
2022
entrez:
27
8
2022
Statut:
ppublish
Résumé
Platelet-activating factor (PAF) is a phospholipid-derived mediator with an established role in multiple inflammatory states. PAF is synthesized and secreted by multiple cell types and is then rapidly hydrolyzed and degraded to an inactive metabolite, lyso-PAF, by the enzyme PAF acetylhydrolase. In addition to its role in platelet aggregation and activation, PAF contributes to allergic and nonallergic inflammatory diseases such as anaphylaxis, sepsis, cardiovascular disease, neurological disease, and malignancy as demonstrated in multiple animal models and, increasingly, in human disease states. Recent research has demonstrated the importance of the PAF pathway in multiple conditions including the prediction of severe pediatric anaphylaxis, effects on blood-brain barrier permeability, effects on reproduction, ocular diseases, and further understanding of its role in cardiovascular risk. Investigation of PAF as both a biomarker and a therapeutic target continues because of the need for directed management of inflammation. Collectively, studies have shown that therapies focused on the PAF pathway have the potential to provide targeted and effective treatments for multiple inflammatory conditions.
Substances chimiques
Platelet Activating Factor
0
1-Alkyl-2-acetylglycerophosphocholine Esterase
EC 3.1.1.47
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1189-1202Informations de copyright
© 2022 International Union of Biochemistry and Molecular Biology.
Références
Benveniste J, Henson PM, Cochrane CG. Leukocyte-dependent histamine release from rabbit platelets. The role of IgE, basophils, and a platelet-activating factor. J Exp Med. 1972;136:1356-77.
Benveniste J. Passage of immune complexes through vascular walls. Evidence for the role of an immediate hypersensitivity mechanism and its mediator: platelet-activating factor. Rheumatology. 1975;6:293-302.
Benveniste J, Le Couedic JP, Kamoun P. Letter: aggregation of human platelets by platelet-activating factor. Lancet. 1975;1:344-5.
Venable ME, Zimmerman GA, McIntyre TM, Prescott SM. Platelet-activating factor: a phospholipid autacoid with diverse actions. J Lipid Res. 1993;34:691-702.
Snyder F, Lee TC, Blank M, Malone B, Woodard D, Robinson M. Platelet-activating factor: alternate pathways of biosynthesis, mechanism of inactivation, and reacylation of lyso-PAF with arachidonate. Adv Prostaglandin Thromboxane Leukot Res. 1985;15:693-6.
Vadas P, Gold M, Perelman B, Liss GM, Lack G, Blyth T, et al. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. N Engl J Med. 2008;358:28-35.
Marathe GK, Prescott SM, Zimmerman GA, McIntyre TM. Oxidized LDL contains inflammatory PAF-like phospholipids. Trends Cardiovasc Med. 2001;11:139-42.
Palgan K, Bartuzi Z. Platelet activating factor in allergies. Int J Immunopathol Pharmacol. 2015;28:584-9.
Travers JB, Rohan JG, Sahu RP. New insights into the pathologic roles of the platelet-activating factor system. Front Endocrinol (Lausanne). 2021;12:624132.
Karasawa K, Harada A, Satoh N, Inoue K, Setaka M. Plasma platelet activating factor-acetylhydrolase (PAF-AH). Prog Lipid Res. 2003;42:93-114.
Blank ML, Cress EA, Whittle T, Snyder F. In vivo metabolism of a new class of biologically active phospholipids: 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine, a platelet activating-hypotensive phospholipid. Life Sci. 1981;29:769-75.
Tjoelker LW, Wilder C, Eberhardt C, Stafforini DM, Dietsch G, Schimpf B, et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature. 1995;374:549-53.
Hattori K, Hattori M, Adachi H, Tsujimoto M, Arai H, Inoue K. Purification and characterization of platelet-activating factor acetylhydrolase II from bovine liver cytosol. J Biol Chem. 1995;270:22308-13.
Hattori M, Adachi H, Tsujimoto M, Arai H, Inoue K. The catalytic subunit of bovine brain platelet-activating factor acetylhydrolase is a novel type of serine esterase. J Biol Chem. 1994;269:23150-5.
Stafforini DM, McIntyre TM, Carter ME, Prescott SM. Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor. J Biol Chem. 1987;262:4215-22.
Yamada Y, Stafforini DM, Imaizumi T, Zimmerman GA, McIntyre TM, Prescott SM. Characterization of the platelet-activating factor acetylhydrolase from human plasma by heterologous expression in Xenopus laevis oocytes. Proc Natl Acad Sci USA. 1994;91:10320-4.
Pritchard PH. The degradation of platelet-activating factor by high-density lipoprotein in rat plasma. Effect of ethynyloestradiol administration. Biochem J. 1987;246:791-4.
Upton JEM, Hoang JA, Leon-Ponte M, Finkelstein Y, Du YJ, Adeli K, et al. Platelet-activating factor acetylhydrolase is a biomarker of severe anaphylaxis in children. Allergy. 2022. Online ahead of print. doi: 10.1111/all.15308.
Stafforini DM, Satoh K, Atkinson DL, Tjoelker LW, Eberhardt C, Yoshida H, et al. Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase. J Clin Invest. 1996;97:2784-91.
Balta G, Gurgey A, Kudayarov DK, Tunc B, Altay C. Evidence for the existence of the PAF acetylhydrolase mutation (Val279Phe) in non-Japanese populations: a preliminary study in Turkey, Azerbaijan, and Kyrgyzstan. Thromb Res. 2001;101:231-4.
Stafforini DM, Numao T, Tsodikov A, Vaitkus D, Fukuda T, Watanabe N, et al. Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma. J Clin Invest. 1999;103:989-97.
Perelman B, Adil A, Vadas P. Relationship between platelet activating factor acetylhydrolase activity and apolipoprotein B levels in patients with peanut allergy. Allergy Asthma Clin Immunol. 2014;10:20.
Gill P, Jindal NL, Jagdis A, Vadas P. Platelets in the immune response: revisiting platelet-activating factor in anaphylaxis. J Allergy Clin Immunol. 2015;135:1424-32.
Honda Z, Ishii S, Shimizu T. Platelet-activating factor receptor. J Biochem. 2002;131:773-9.
Howard KM. Platelet-activating factor receptor. In: Lennarz WJ, Lane MD, editors. Encyclopedia of Biological Chemistry II. 2nd ed. San Diego, CA: Academic Press; 2013.
Deo DD, Bazan NG, Hunt JD. Activation of platelet-activating factor receptor-coupled G alpha q leads to stimulation of Src and focal adhesion kinase via two separate pathways in human umbilical vein endothelial cells. J Biol Chem. 2004;279:3497-508.
Moritoki H, Hisayama T, Takeuchi S, Miyano H, Kondoh W. Involvement of nitric oxide pathway in the PAF-induced relaxation of rat thoracic aorta. Br J Pharmacol. 1992;107:196-201.
Vadas P, Pruzanski W. Phospholipase A2 activation is the pivotal step in the effector pathway of inflammation. Adv Exp Med Biol. 1990;275:83-101.
Kajiwara N, Sasaki T, Bradding P, Cruse G, Sagara H, Ohmori K, et al. Activation of human mast cells through the platelet-activating factor receptor. J Allergy Clin Immunol. 2010;125(5):1137-1145.e6.
Nilsson G, Metcalfe DD, Taub DD. Demonstration that platelet-activating factor is capable of activating mast cells and inducing a chemotactic response. Immunology. 2000;99:314-9.
Yoshikawa M, Matsumoto K, Iida M, Akasawa A, Moriyama H, Saito H. Effect of extracellular matrix proteins on platelet-activating factor-induced eosinophil chemotaxis. Int Arch Allergy Immunol. 2002;128(Suppl 1):3-11.
Belanger C, Elimam H, Lefebvre J, Borgeat P, Marleau S. Involvement of endogenous leukotriene B4 and platelet-activating factor in polymorphonuclear leucocyte recruitment to dermal inflammatory sites in rats. Immunology. 2008;124:295-303.
Bastien Y, Toledano BJ, Mehio N, Cameron L, Lamoukhaid B, Renzi P, et al. Detection of functional platelet-activating factor receptors on human tonsillar B lymphocytes. J Immunol. 1999;162:5498-505.
Koltai M, Hosford D, Guinot P, Esanu A, Braquet P. PAF. A review of its effects, antagonists and possible future clinical implications (part II). Drugs. 1991;42:174-204.
Brailoiu E, Barlow CL, Ramirez SH, Abood ME, Brailoiu GC. Effects of platelet-activating factor on brain microvascular endothelial cells. Neuroscience. 2018;377:105-13.
Gaumond F, Fortin D, Stankova J, Rola-Pleszczynski M. Differential signaling pathways in platelet-activating factor-induced proliferation and interleukin-6 production by rat vascular smooth muscle cells. J Cardiovasc Pharmacol. 1997;30:169-75.
Vadas P, Perelman B. Effect of epinephrine on platelet-activating factor-stimulated human vascular smooth muscle cells. J Allergy Clin Immunol. 2012;129:1329-33.
Montrucchio G, Alloatti G, Camussi G. Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev. 2000;80:1669-99.
Gao T, Yu Y, Cong Q, Wang Y, Sun M, Yao L, et al. Human mesenchymal stem cells in the tumour microenvironment promote ovarian cancer progression: the role of platelet-activating factor. BMC Cancer. 2018;18:999.
Deuster E, Hysenaj I, Kahaly M, Schmoeckel E, Mayr D, Beyer S, et al. The platelet-activating factor Receptor's association with the outcome of ovarian cancer patients and its experimental inhibition by Rupatadine. Cell. 2021;10(9):2337.
Archer CB, MacDonald DM, Morley J, Page CP, Paul W, Sanjar S. Effects of serum albumin, indomethacin and histamine H1-antagonists on Paf-acether-induced inflammatory responses in the skin of experimental animals and man. Br J Pharmacol. 1985;85:109-13.
Archer CB, Page CP, Paul W, Morley J, MacDonald DM. Inflammatory cell accumulation in response to intracutaneous Paf-acether: a mediator of acute and persistent inflammation? Br J Dermatol. 1985;113(Suppl 28):133-5.
Archer CB, Frohlich W, Page CW, Paul W, Morley J, MacDonald DM. Synergistic interaction between prostaglandins and PAF-acether in experimental animals and man. Prostaglandins. 1984;27:495-501.
Gonzalez-Crussi F, Hsueh W. Experimental model of ischemic bowel necrosis. The role of platelet-activating factor and endotoxin. Am J Pathol. 1983;112:127-35.
Villamediana LM, Sanz E, Fernandez-Gallardo S, Caramelo C, Sanchez Crespo M, Braquet P, et al. Effects of the platelet-activating factor antagonist BN 52021 on the hemodynamics of rats with experimental cirrhosis of the liver. Life Sci. 1986;39:201-5.
Novo S, Pernice C, Geraci AM, Longo B, Barbagallo CM, Caruso R, et al. Risk factors, ageing, and asymptomatic carotid plaque. Cardiologia. 1995;40:263-72.
Wang M, Shibamoto T, Kuda Y, Tanida M, Zhang T, Song J, et al. The responses of pulmonary and systemic circulation and airway to allergic mediators in anesthetized rats. Biol Pharm Bull. 2016;39:556-63.
Criscuoli M, Subissi A. Paf-acether-induced death in mice: involvement of arachidonate metabolites and beta-adrenoceptors. Br J Pharmacol. 1987;90:203-9.
Sanchez-Crespo M, Alonso F, Inarrea P, Alvarez V, Egido J. Vascular actions of synthetic PAF-acether (a synthetic platelet-activating factor) in the rat: evidence for a platelet independent mechanism. Immunopharmacology. 1982;4:173-85.
Siren AL, Feuerstein G. Effects of PAF and BN 52021 on cardiac function and regional blood flow in conscious rats. Am J Physiol. 1989;257:H25-32.
Feuerstein G, Lux WE Jr, Snyder F, Ezra D, Faden AI. Hypotension produced by platelet-activating factor is reversed by thyrotropin-releasing hormone. Circ Shock. 1984;13:255-60.
Sybertz EJ, Watkins RW, Vemulapalli S, Baum T, Chiu PJ, Barnett A. AGEPC, a vasodilator phospholipid with profound circulatory actions. Prog Clin Biol Res. 1986;219:133-56.
Accurso FJ, Abman SH, Wilkening RB, Worthen GS, Henson P. Fetal pulmonary vasodilation after exogenous platelet-activating factor. J Appl Physiol. 1991;1985(70):778-87.
Becker K, Lueddeckens G, Grupe R, Forster W. PAF-induced death in NMRI mice-a suitable shock model for testing new PAF receptor antagonists. Correlation with eicosanoid related substances. Prostaglandins Leukot Essent Fatty Acids. 1993;48:265-71.
Nagaoka J, Harada K, Kimura A, Kobayashi S, Murakami M, Yoshimura T, et al. Inhibitory effects of the novel platelet activating factor receptor antagonist, 1-ethyl-2-[N-(2-methoxy)benzoyl-N-[(2R)-2-methoxy-3-(4- octadecylcarbamoyloxy) piperidinocarbonyloxypropyloxy]carbonyl] aminomethyl-pyridinium chloride, in several experimentally induced shock models. Arzneimittelforschung. 1991;41:719-24.
Fletcher JR, DiSimone AG, Earnest MA. Platelet activating factor receptor antagonist improves survival and attenuates eicosanoid release in severe endotoxemia. Ann Surg. 1990;211:312-6.
Ebara T, Miura K, Matsuura T, Imanishi M, Yamano Y, Kim S, et al. Role of platelet-activating factor and prostanoids in hemodynamic changes in rat experimental endotoxic shock. Jpn J Pharmacol. 1996;71:247-53.
Ruggiero V, Chiapparino C, Manganello S, Pacello L, Foresta P, Martelli EA. Beneficial effects of a novel platelet-activating factor receptor antagonist, ST 899, on endotoxin-induced shock in mice. Shock. 1994;2:275-80.
Mozes T, Heiligers JP, Tak CJ, Zijlstra FJ, Ben-Efraim S, Saxena PR, et al. Platelet activating factor is one of the mediators involved in endotoxic shock in pigs. J Lipid Mediat. 1991;4:309-25.
Mozes T, Ben-Efraim S, Bonta IL. Lethal and non-lethal course of endotoxic shock is determined by interactions between tumor necrosis factor, platelet activating factor and eicosanoids. Pathol Biol (Paris). 1992;40:807-12.
Quinn JV, Slotman GJ. Platelet-activating factor and arachidonic acid metabolites mediate tumor necrosis factor and eicosanoid kinetics and cardiopulmonary dysfunction during bacteremic shock. Crit Care Med. 1999;27:2485-94.
Carrick JB, Morris DD, Moore JN. Administration of a receptor antagonist for platelet-activating factor during equine endotoxaemia. Equine Vet J. 1993;25:152-7.
Soares AC, Pinho VS, Souza DG, Shimizu T, Ishii S, Nicoli JR, et al. Role of the platelet-activating factor (PAF) receptor during pulmonary infection with gram negative bacteria. Br J Pharmacol. 2002;137:621-8.
Clavijo LC, Carter MB, Matheson PJ, Wills-Frank LA, Wilson MA, Wead WB, et al. Platelet-activating factor and bacteremia-induced pulmonary hypertension. J Surg Res. 2000;88:173-80.
Carter MB, Wilson MA, Wead WB, Garrison RN. Platelet-activating factor mediates pulmonary macromolecular leak following intestinal ischemia-reperfusion. J Surg Res. 1996;60:403-8.
McCullers JA, Rehg JE. Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. J Infect Dis. 2002;186:341-50.
Souza DG, Fagundes CT, Sousa LP, Amaral FA, Souza RS, Souza AL, et al. Essential role of platelet-activating factor receptor in the pathogenesis of dengue virus infection. Proc Natl Acad Sci USA. 2009;106:14138-43.
Shibamoto T, Liu W, Cui S, Zhang W, Takano H, Kurata Y. PAF, rather than histamine, participates in mouse anaphylactic hypotension. Pharmacology. 2008;82:114-20.
Wang M, Shibamoto T, Tanida M, Kuda Y, Kurata Y. Mouse anaphylactic shock is caused by reduced cardiac output, but not by systemic vasodilatation or pulmonary vasoconstriction, via PAF and histamine. Life Sci. 2014;116:98-105.
Arias K, Baig M, Colangelo M, Chu D, Walker T, Goncharova S, et al. Concurrent blockade of platelet-activating factor and histamine prevents life-threatening peanut-induced anaphylactic reactions. J Allergy Clin Immunol. 2009;124(307-314):314.e301-2.
Ishii S, Nagase T, Tashiro F, Ikuta K, Sato S, Waga I, et al. Bronchial hyperreactivity, increased endotoxin lethality and melanocytic tumorigenesis in transgenic mice overexpressing platelet-activating factor receptor. EMBO J. 1997;16:133-42.
Ishii S, Shimizu T. Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice. Prog Lipid Res. 2000;39:41-82.
Ishii S, Kuwaki T, Nagase T, Maki K, Tashiro F, Sunaga S, et al. Impaired anaphylactic responses with intact sensitivity to endotoxin in mice lacking a platelet-activating factor receptor. J Exp Med. 1998;187:1779-88.
Talvani A, Santana G, Barcelos LS, Ishii S, Shimizu T, Romanha AJ, et al. Experimental Trypanosoma cruzi infection in platelet-activating factor receptor-deficient mice. Microbes Infect. 2003;5:789-96.
Santiago HC, Braga Pires MF, Souza DG, Roffe E, Cortes DF, Tafuri WL, et al. Platelet activating factor receptor-deficient mice present delayed interferon-gamma upregulation and high susceptibility to Leishmania amazonensis infection. Microbes Infect. 2006;8:2569-77.
Souza DG, Pinho V, Soares AC, Shimizu T, Ishii S, Teixeira MM. Role of PAF receptors during intestinal ischemia and reperfusion injury. A comparative study between PAF receptor-deficient mice and PAF receptor antagonist treatment. Br J Pharmacol. 2003;139:733-40.
Fukuda S, Yasu T, Predescu DN, Schmid-Schonbein GW. Mechanisms for regulation of fluid shear stress response in circulating leukocytes. Circ Res. 2000;86:E13-8.
Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med. 2002;30:S294-301.
Lordan R, Tsoupras A, Zabetakis I, Demopoulos CA. Forty years since the structural elucidation of platelet-activating factor (PAF): historical, current, and future research perspectives. Molecules. 2019;24:4414.
Ashraf MA, Nookala V. StatPearls. Treasure Island, FL: StatPearls Publishing LLC; 2022.
Kasperska-Zajac A, Brzoza Z, Rogala B. Platelet-activating factor (PAF): a review of its role in asthma and clinical efficacy of PAF antagonists in the disease therapy. Recent Pat Inflamm Allergy Drug Discov. 2008;2:72-6.
Pravettoni V, Piantanida M, Primavesi L, Forti S, Pastorello EA. Basal platelet-activating factor acetylhydrolase: prognostic marker of severe hymenoptera venom anaphylaxis. J Allergy Clin Immunol. 2014;133:1218-20.
Piwowarek KL, Rzeszotarska A, Korsak JL, Juszkiewicz A, Chcialowski A, Kruszewski J. Clinical significance of plasma PAF acetylhydrolase activity measurements as a biomarker of anaphylaxis: cross-sectional study. PLoS One. 2021;16:e0256168.
Bilo MB, Corsi A, Martini M, Danieli MG, Alia S, Di Paolo A, et al. Platelet-activating factor acetylhydrolase: a biomarker in hymenoptera venom allergy? Allergy. 2022;77:1032-5.
Vladislavovna N, Ekaterina Karenovna E, Natalia Sergeevna S, Zarema Grigorievna K, Anastasia K. Platelet-activating factor-Acetylhydrolase gene (PLA2G7) expression in children with a history of food anaphylaxis. J Allergy Ther. 2015;6:211.
Munoz-Cano RM, Casas-Saucedo R, Valero Santiago A, Bobolea I, Ribo P, Mullol J. Platelet-activating factor (PAF) in allergic rhinitis: clinical and therapeutic implications. J Clin Med. 2019;8:1338.
Ulambayar B, Yang EM, Cha HY, Shin YS, Park HS, Ye YM. Increased platelet activating factor levels in chronic spontaneous urticaria predicts refractoriness to antihistamine treatment: an observational study. Clin Transl Allergy. 2019;9:33.
Davidson MH, Corson MA, Alberts MJ, Anderson JL, Gorelick PB, Jones PH, et al. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol. 2008;101:51F-7F.
Chang JG. PLAC test for Lp-PLA2 activity to predict coronary heart disease. Am Fam Physician. 2020;101:44-6.
Izaki S, Yamamoto T, Goto Y, Ishimaru S, Yudate F, Kitamura K, et al. Platelet-activating factor and arachidonic acid metabolites in psoriatic inflammation. Br J Dermatol. 1996;134:1060-4.
Jiang R, Chen S, Shen Y, Wu J, Chen S, Wang A, et al. Higher levels of lipoprotein associated phospholipase A2 is associated with increased prevalence of cognitive impairment: the APAC study. Sci Rep. 2016;6:33073.
Amunugama K, Pike DP, Ford DA. The lipid biology of sepsis. J Lipid Res. 2021;62:100090.
Sharif NA. PAF-induced inflammatory and immuno-allergic ophthalmic diseases and their mitigation with PAF receptor antagonists: cell and nuclear effects. Biofactors. 2022;48:1226-49.
Roudebush WE. The emerging role of platelet-activating factor on the regulation of embryonic ploidy via apoptosis. J Biomed Sci. 2021;3:OAJBS.ID.000252.
Upton J, Vadas P. Potential therapeutic strategies for severe anaphylaxis targeting platelet-activating factor and PAF Acetylhydrolase. Curr Treat Options Allergy. 2014;1:232-46.
Zheng GH, Xiong SQ, Chen HY, Mei LJ, Wang T. Associations of platelet-activating factor acetylhydrolase (PAF-AH) gene polymorphisms with circulating PAF-AH levels and risk of coronary heart disease or blood stasis syndrome in the Chinese Han population. Mol Biol Rep. 2014;41:7141-51.
Santoso A, Maulana R, Alzahra F, Maghfirah I, Putrinarita AD, Heriansyah T. Associations between four types of single-nucleotide polymorphisms in PLA2G7 gene and clinical atherosclerosis: a meta-analysis. Am J Cardiovasc Dis. 2017;7:122-33.
Demopoulos C, Antonopoulou S, Theoharides TC. COVID-19, microthromboses, inflammation, and platelet activating factor. Biofactors. 2020;46:927-33.
Detopoulou P, Demopoulos CA, Antonopoulou S. Micronutrients, phytochemicals and Mediterranean diet: a potential protective role against COVID-19 through modulation of PAF actions and metabolism. Nutrients. 2021;13:462.
Minneci PC, Deans KJ, Banks SM, Eichacker PQ, Natanson C. Should we continue to target the platelet-activating factor pathway in septic patients? Crit Care Med. 2004;32:585-8.
Opal S, Laterre PF, Abraham E, Francois B, Wittebole X, Lowry S, et al. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit Care Med. 2004;32:332-41.
Taggart DP, Browne SM, Wade DT, Halligan PW. Neuroprotection during cardiac surgery: a randomised trial of a platelet activating factor antagonist. Heart. 2003;89:897-900.
Abu-Zidan FM, Windsor JA. Lexipafant and acute pancreatitis: a critical appraisal of the clinical trials. Eur J Surg. 2002;168:215-9.
Yeo A, Li L, Warren L, Aponte J, Fraser D, King K, et al. Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib. PLoS One. 2017;12:e0182115.
Stack WA, Jenkins D, Vivet P, Hawkey CJ. Lack of effectiveness of the platelet-activating factor antagonist SR27417A in patients with active ulcerative colitis: a randomized controlled trial. The platelet activating factor antagonist study Group in Ulcerative Colitis. Gastroenterology. 1998;115:1340-5.
Hilliquin P, Chermat-Izard V, Menkes CJ. A double blind, placebo controlled study of a platelet activating factor antagonist in patients with rheumatoid arthritis. J Rheumatol. 1998;25:1502-7.
Marathe GK, Pandit C, Lakshmikanth CL, Chaithra VH, Jacob SP, D'Souza CJ. To hydrolyze or not to hydrolyze: the dilemma of platelet-activating factor acetylhydrolase. J Lipid Res. 2014;55:1847-54.
Stafforini DM, Zimmerman GA. Unraveling the PAF-AH/Lp-PLA2 controversy. J Lipid Res. 2014;55:1811-4.
Tokumura A, Sumida T, Toujima M, Kogure K, Fukuzawa K. Platelet-activating factor (PAF)-like oxidized phospholipids: relevance to atherosclerosis. Biofactors. 2000;13:29-33.
Nomikos T, Fragopoulou E, Antonopoulou S, Panagiotakos DB. Mediterranean diet and platelet-activating factor: a systematic review. Clin Biochem. 2018;60:1-10.
Dong Y, Zhang J, Wang Y, Zhao L, Li R, Wei C, et al. Effect of Ginkgolide in ischemic stroke patients with large artery atherosclerosis: results from a randomized trial. CNS Neurosci Ther. 2021;27:1561-9.
Zhang X, Zhong W, Ma X, Zhang X, Chen H, Wang Z, et al. Ginkgolide with intravenous alteplase thrombolysis in acute ischemic stroke improving neurological function: a multicenter, cluster-randomized trial (GIANT). Front Pharmacol. 2021;12:792136.